Cypress Capital Group Has $3.42 Million Stake in Bristol Myers Squibb Company $BMY

Cypress Capital Group boosted its position in shares of Bristol Myers Squibb Company (NYSE:BMY) by 2.2% in the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 73,839 shares of the biopharmaceutical company’s stock after acquiring an additional 1,570 shares during the period. Cypress Capital Group’s holdings in Bristol Myers Squibb were worth $3,418,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Bill Few Associates Inc. lifted its position in Bristol Myers Squibb by 6.4% during the 2nd quarter. Bill Few Associates Inc. now owns 10,595 shares of the biopharmaceutical company’s stock worth $490,000 after acquiring an additional 633 shares during the last quarter. Allspring Global Investments Holdings LLC lifted its position in Bristol Myers Squibb by 193.6% during the 2nd quarter. Allspring Global Investments Holdings LLC now owns 535,902 shares of the biopharmaceutical company’s stock worth $25,461,000 after acquiring an additional 353,392 shares during the last quarter. RHS Financial LLC acquired a new position in Bristol Myers Squibb during the 2nd quarter worth $459,000. OFI Invest Asset Management lifted its position in Bristol Myers Squibb by 33.7% during the 2nd quarter. OFI Invest Asset Management now owns 1,689 shares of the biopharmaceutical company’s stock worth $78,000 after acquiring an additional 426 shares during the last quarter. Finally, Sippican Capital Advisors lifted its position in Bristol Myers Squibb by 1.4% during the 2nd quarter. Sippican Capital Advisors now owns 56,392 shares of the biopharmaceutical company’s stock worth $2,610,000 after acquiring an additional 770 shares during the last quarter. Institutional investors and hedge funds own 76.41% of the company’s stock.

Bristol Myers Squibb Stock Performance

NYSE BMY opened at $44.01 on Monday. The stock has a market cap of $89.57 billion, a P/E ratio of 17.74, a PEG ratio of 2.26 and a beta of 0.33. The company’s 50-day simple moving average is $46.26 and its 200 day simple moving average is $47.96. Bristol Myers Squibb Company has a twelve month low of $42.96 and a twelve month high of $63.33. The company has a quick ratio of 1.11, a current ratio of 1.21 and a debt-to-equity ratio of 2.54.

Bristol Myers Squibb (NYSE:BMY) last posted its earnings results on Thursday, July 31st. The biopharmaceutical company reported $1.46 earnings per share for the quarter, beating analysts’ consensus estimates of $1.07 by $0.39. The business had revenue of $12.27 billion for the quarter, compared to analysts’ expectations of $11.32 billion. Bristol Myers Squibb had a net margin of 10.58% and a return on equity of 80.04%. The firm’s revenue for the quarter was up .6% on a year-over-year basis. During the same quarter in the previous year, the firm posted $2.07 earnings per share. Bristol Myers Squibb has set its FY 2025 guidance at 6.350-6.650 EPS. As a group, research analysts forecast that Bristol Myers Squibb Company will post 6.74 earnings per share for the current fiscal year.

Bristol Myers Squibb Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Monday, November 3rd. Investors of record on Friday, October 3rd will be paid a $0.62 dividend. The ex-dividend date of this dividend is Friday, October 3rd. This represents a $2.48 dividend on an annualized basis and a yield of 5.6%. Bristol Myers Squibb’s payout ratio is presently 100.00%.

Analyst Ratings Changes

BMY has been the subject of a number of research analyst reports. Morgan Stanley reaffirmed a “hold” rating on shares of Bristol Myers Squibb in a research report on Thursday, July 31st. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Bristol Myers Squibb in a research report on Saturday, September 27th. Daiwa Capital Markets lowered shares of Bristol Myers Squibb from an “outperform” rating to a “neutral” rating and set a $42.00 price objective for the company. in a research report on Tuesday, August 5th. Daiwa America lowered shares of Bristol Myers Squibb from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, August 5th. Finally, Citigroup cut their price objective on shares of Bristol Myers Squibb from $51.00 to $47.00 and set a “neutral” rating for the company in a research report on Friday, August 1st. One research analyst has rated the stock with a Strong Buy rating, five have given a Buy rating and fifteen have given a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Hold” and an average price target of $57.14.

Insiders Place Their Bets

In other Bristol Myers Squibb news, EVP David V. Elkins sold 56,000 shares of the company’s stock in a transaction dated Tuesday, September 2nd. The shares were sold at an average price of $47.33, for a total transaction of $2,650,480.00. Following the sale, the executive vice president directly owned 167,379 shares of the company’s stock, valued at approximately $7,922,048.07. This represents a 25.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. 0.07% of the stock is currently owned by insiders.

Bristol Myers Squibb Company Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.